{
    "clinical_study": {
        "@rank": "63574", 
        "arm_group": {
            "arm_group_label": "PASCALLERG\u00ae tablets in patients with hay fever", 
            "description": "Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study."
        }, 
        "brief_summary": {
            "textblock": "The aim of this observational study is to document the therapeutic use of PASCALLERG \u00ae for\n      hay fever. Based on the survey is a decrease in disease-specific symptoms when taking\n      PASCALLERG \u00ae over a period of 4 weeks will be documented. In addition to the compatibility\n      can be assessed."
        }, 
        "brief_title": "Observational Study With PASCALLERG \u00ae in Patients With Hay Fever", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "Hay Fever", 
        "condition_browse": {
            "mesh_term": [
                "Fever", 
                "Rhinitis, Allergic, Seasonal"
            ]
        }, 
        "detailed_description": {
            "textblock": "There are documented male and female patients over the age of one year who suffer from hay\n      fever. The traetment time is about a period of 4 weeks with PASCALLERG\u00ae tablets."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  hay fever\n\n        Exclusion Criteria:\n\n          -  Lactose intolerance and / or\n\n          -  Chromium hypersensitivity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "1 Year", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "patients from natural practioners and doctors from Germany"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01660737", 
            "org_study_id": "180A12PALL"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hay fever", 
            "Pascallerg"
        ], 
        "lastchanged_date": "August 13, 2012", 
        "location": {
            "contact": {
                "last_name": "Jennifer Lebert, Study Manager", 
                "phone": "0049(641)-7960955"
            }, 
            "facility": {
                "address": {
                    "city": "Gie\u00dfen", 
                    "country": "Germany", 
                    "zip": "35390"
                }, 
                "name": "Jennifer Lebert"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Observational Study With PASCALLERG \u00ae in Patients With Hay Fever", 
        "other_outcome": {
            "measure": "Dosage of Pascallerg", 
            "safety_issue": "No", 
            "time_frame": "on average 4 weeks"
        }, 
        "overall_contact": {
            "email": "Jennifer.lebert@pascoe.de", 
            "last_name": "Jennifer Lebert, Study Manager", 
            "phone": "0049(641)-7960955"
        }, 
        "overall_contact_backup": {
            "email": "Bianka.Krick@pascoe.de", 
            "last_name": "Bianka Krick", 
            "phone": "0049(641)-7960963"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Request of Efficacy using a 4-stage scale (very good efficacy, good efficacy, moderate efficacy, no efficacy)", 
                "measure": "Efficacy of Pascallerg", 
                "safety_issue": "No", 
                "time_frame": "on average 4 weeks"
            }, 
            {
                "description": "Request of Tolerability using a 2-stage scale (very good tolerability, bad tolerability)", 
                "measure": "Tolerability", 
                "safety_issue": "No", 
                "time_frame": "on average 4 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01660737"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Influence of allergy on the general well-being (scale from 0-no influence to 10 strong influence)", 
                "measure": "Numerical Rating Scale", 
                "safety_issue": "No", 
                "time_frame": "on average 4 weeks"
            }, 
            {
                "description": "Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)", 
                "measure": "Dry eyes", 
                "safety_issue": "No", 
                "time_frame": "on average 4 weeks"
            }, 
            {
                "description": "Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)", 
                "measure": "Itching eyes", 
                "safety_issue": "No", 
                "time_frame": "on average 4 weeks"
            }, 
            {
                "description": "Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)", 
                "measure": "Burning eyes", 
                "safety_issue": "No", 
                "time_frame": "on average 4 weeks"
            }, 
            {
                "description": "Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)", 
                "measure": "Bronchial complaints", 
                "safety_issue": "No", 
                "time_frame": "on average 4 weeks"
            }, 
            {
                "description": "Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)", 
                "measure": "Sneezing", 
                "safety_issue": "No", 
                "time_frame": "on average 4 weeks"
            }, 
            {
                "description": "Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)", 
                "measure": "Rhinitis", 
                "safety_issue": "No", 
                "time_frame": "on average 4 weeks"
            }, 
            {
                "description": "Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)", 
                "measure": "Fatigue / Tiredness", 
                "safety_issue": "No", 
                "time_frame": "on average 4 weeks"
            }, 
            {
                "description": "Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)", 
                "measure": "Headache", 
                "safety_issue": "No", 
                "time_frame": "on average 4 weeks"
            }, 
            {
                "description": "Request Scale (0=not present, 1=mild, 2=moderate, 3=strong)", 
                "measure": "Tearing eyes", 
                "safety_issue": "No", 
                "time_frame": "on average 4 weeks"
            }
        ], 
        "source": "Pascoe Pharmazeutische Praeparate GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pascoe Pharmazeutische Praeparate GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2012"
    }
}